Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma

Documenti analoghi

• A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma
  di: Liu, Xiaoqian, et al.
  Pubblicazione: (2021)
• Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed/refractory acute myeloid leukemia
  di: Lin, Guoqiang, et al.
  Pubblicazione: (2021)
• First Allogeneic CAR T‐Cell Therapy Impresses in Relapsed/Refractory Lymphoma
  Pubblicazione: (2020)
• KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
  di: Wang, Michael, et al.
  Pubblicazione: (2020)
• Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
  di: Ramos, Carlos A., et al.
  Pubblicazione: (2020)